Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay

BACKGROUND: The 21-gene recurrence score (RS) (Oncotype DX(®); Genomic Health, Redwood City, CA) partitions hormone receptor positive, node negative breast cancers into three risk groups for recurrence. The Anne Arundel Medical Center (AAMC) model has previously been shown to accurately predict RS r...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Ann Oncol
Huvudupphovsmän: Gage, M M, Mylander, W C, Rosman, M, Fujii, T, Le Du, F, Raghavendra, A, Sinha, A K, Espinosa Fernandez, J R, James, A, Ueno, N T, Tafra, L, Jackson, R S
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2018
Ämnen:
Original articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961181/
https://ncbi.nlm.nih.gov/pubmed/29788166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy074
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk